NextCell Pharma AB (“NXTCL”) announces that Invest Stockholm has now placed NXTCL on the Life Science Hotlist.
The Stockholm-Uppsala Life Science Investment Hotlist is curated by Invest Stockholm and lists the most promising and innovative companies active in the field of life science. NXTCL with both its stem cell banking and drug development business is an ideal candidate for this list.
The company develops novel treatments with stem cells from the umbilical cord. In umbilical cord and umbilical cord tissue there are young and viable stem cells that can be collected without any medical intervention. As such we have developed a drug candidate called ProTrans which is our first product and is currently being tested in a Phase I/II clinical trial on patients suffering from Type 1 diabetes. NXTCL also operates Cellaviva, the first Swedish family saving stem cell bank. Prospective parents are offered a service for saving their child’s stem cells for the family and the child’s future medical need. Family stem cell banking and cord blood banking is a proven business model.
“Being on the hotlist is a recognition of the work we have been doing over the past few years. It also gives us increased exposure to potential investors and collaborators,” Says Leo Groenewegen, Business Development Manager.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595